Novavax And The NIH Agree To Evaluate A Virus-like Particle (VLP) Vaccine Candidate Against The Novel Influenza A (H1N1) Virus

Novavax, Inc. (Nasdaq: NVAX) and the Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) have signed an agreement to cooperate in the evaluation of a virus-like particle (VLP) vaccine candidate against the novel influenza A (H1N1) virus. Novavax has produced influenza A (H1N1) VLP vaccine against the strain recommended by the Centers for Disease Control and Prevention (CDC).

More: continued here

Filed under: Immune System / Vaccines on June 5th, 2009